Affimed N.V. is at the forefront of developing innate cell engagers (ICE®) that activate and redirect innate immune cells to fight cancer. The company's innovative approach focuses on leveraging the untapped power of the innate immune system, with a particular emphasis on activating NK cells and macrophages through tumor-specific targeting. This strategy has led to the development of a robust pipeline of therapies aimed at both solid and liquid tumors.
- AFM24: Targeting EGFR-expressing solid tumors, AFM24 has shown encouraging early efficacy in heavily pretreated NSCLC patients, with a manageable safety profile. The therapy is being studied in combination with atezolizumab, a checkpoint inhibitor, in a Phase 2 study for relapsed/refractory NSCLC.
- Acimtamig (AFM13): In combination with AlloNK® cells, AFM13 is being evaluated in a Phase 2 study for relapsed/refractory Hodgkin lymphoma, demonstrating an overall response rate of 83.3%.
- AFM28: Focused on relapsed/refractory AML, AFM28 has shown promise in early clinical trials, with a complete response rate observed in patients at higher dose levels.
Affimed's leadership team, with a proven track record in life sciences and biotechnology, is steering the company towards meaningful clinical data readouts in 2024. The company's commitment to advancing cancer immunotherapy is underscored by its collaborations and the pursuit of innovative treatment modalities that could significantly impact patient outcomes in oncology.
